A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Lynda Spelmana Veracity Clinical Research, Brisbane, AustraliaView further author information

Alan Brnabicc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information

Nicole Burkhardtc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information

Elisabeth Riedld Eli Lilly Ges.m.b.H, Vienna, Austria;e Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information

Peter Foleyf Skin Health Institute, Carlton, Australia;g The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, AustraliaCorrespondence[email protected]
View further author information

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.